Codexis, Inc. (CDXS)

NASDAQ: CDXS · IEX Real-Time Price · USD
6.06
-0.32 (-5.02%)
Sep 30, 2022 4:00 PM EDT - Market closed
-5.02%
Market Cap 396.89M
Revenue (ttm) 135.02M
Net Income (ttm) -18.94M
Shares Out 65.49M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE 138.89
Dividend n/a
Ex-Dividend Date n/a
Volume 594,681
Open 6.08
Previous Close 6.38
Day's Range 6.05 - 6.43
52-Week Range 6.04 - 42.01
Beta 1.57
Analysts Buy
Price Target 18.74 (+209.2%)
Earnings Date Nov 2, 2022

About CDXS

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance... [Read more...]

Industry Life Sciences Tools & Services
IPO Date Apr 22, 2010
Employees 261
Stock Exchange NASDAQ
Ticker Symbol CDXS
Full Company Profile

Financial Performance

In 2021, Codexis's revenue was $104.75 million, an increase of 51.69% compared to the previous year's $69.06 million. Losses were -$21.28 million, -11.37% less than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for CDXS stock is "Buy." The 12-month stock price forecast is 18.74, which is an increase of 209.24% from the latest price.

Price Target
$18.74
(209.24% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Codexis' 2022 Protein Engineering Forum Showcases Recent Industry Success and Emerging Innovations in the Field

REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the recent hosting ...

2 weeks ago - GlobeNewsWire

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of 71.43% and 1.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Codexis Reports Second Quarter 2022 Financial Results

Total Revenue up 51% and Product Revenue up 135% YOY

1 month ago - GlobeNewsWire

Analysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out for

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Codexis Shares Slide On CEO Transition

Codexis, Inc. (NASDAQ: CDXS) has appointed Dr. Stephen Dilly, Board member, and biotechnology veteran, as President and CEO, effective August 9, 2022. After ten years of leading the transformation and g...

2 months ago - Benzinga

Codexis Announces CEO Transition Effective August 9, 2022

Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis

2 months ago - GlobeNewsWire

Why Codexis Shares Are Slumping Today

Codexis Inc (NASDAQ: CDXS) expects Q2 sales of approximately $38 million and FY22 sales of 135 million to $141 million, below the propr expectation of $152 million - $158 million. FY22 product revenues ...

2 months ago - Benzinga

Codexis stock drops as forecast comes in below Street estimate

Codexis Inc. CDXS shares fell in the extended session Thursday after the biotech company lowered its revenue forecast for the year and said that sales from Pfizer Inc. PFE would come in at the low end o...

2 months ago - Market Watch

Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID™ (nirmatrelvir tablets; rito...

REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the Company has...

2 months ago - GlobeNewsWire

Codexis Announces Preliminary Second Quarter 2022 Results and Updates Guidance

Final financial results for the second quarter to be reported on August 4, 2022 Final financial results for the second quarter to be reported on August 4, 2022

2 months ago - GlobeNewsWire

Codexis (CDXS) Surges 9.7%: Is This an Indication of Further Gains?

Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

3 months ago - Zacks Investment Research

Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Biocon...

Collaboration with Merck published in Science magazine

3 months ago - GlobeNewsWire

Codexis to Participate in Upcoming Healthcare Conferences

REDWOOD CITY, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will ...

4 months ago - GlobeNewsWire

Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of 27.78% and 21.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Codexis Reports First Quarter 2022 Financial Results

Total Revenue up 96% and Product Revenue up 200% YOY; Product Gross Margin Expands to 72%

4 months ago - GlobeNewsWire

Codexis to Present Data Highlighting Three Gene Therapy Programs at the ASGCT 25th Annual Meeting

REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced two poster presentati...

5 months ago - GlobeNewsWire

After Plunging 39.6% in 4 Weeks, Here's Why the Trend Might Reverse for Codexis (CDXS)

Codexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear...

5 months ago - Zacks Investment Research

Codexis to Report First Quarter 2022 Financial Results on May 5

REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report...

5 months ago - GlobeNewsWire

Codexis and seqWell Announce Strategic Investment and Partnership Initiation

REDWOOD CITY, Calif. and BEVERLY, Mass.--(BUSINESS WIRE)--Codexis, Inc. (Nasdaq: CDXS) and seqWell, Inc. today announced the initiation of a strategic partnership and investment to accelerate the commer...

5 months ago - Business Wire

Codexis to Participate in the Cowen 42nd Annual Health Care Conference

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will...

7 months ago - GlobeNewsWire

Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of 11.11% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Codexis Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Record Annual Total Revenue of $104.8M, Representing Eighth Consecutive Year of Revenue Growth

7 months ago - GlobeNewsWire

Earnings Preview: Codexis (CDXS) Q4 Earnings Expected to Decline

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Codexis to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24

REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report i...

7 months ago - GlobeNewsWire

Codexis (CDXS) Surges 6.2%: Is This an Indication of Further Gains?

Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

7 months ago - Zacks Investment Research